PHARMACYCLICS INC
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY14 | FY13 | FY12 | FY11 | FY10 | |
|---|---|---|---|---|---|
| Revenue | $119.4M | $2.8M | $82.0M | $77.9M | $9.3M |
| Operating income | $18.2M | −$53.0M | $11.9M | $47.3M | −$15.6M |
| Net income | $18.3M | −$51.9M | $12.0M | $41.7M | −$15.0M |
| Total assets | $1.06B | $768.8M | $355.1M | $116.4M | — |
| Total liabilities | $230.9M | $141.1M | $92.6M | $14.7M | — |
| Equity | $829.2M | $627.6M | $132.1M | $101.7M | $66.8M |
| EPS (diluted) | $0.23 | $-0.73 | $0.17 | $0.58 | $-0.31 |
| Shares out. | 74.8M | 70.5M | 69.5M | 67.9M | 48.3M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2014- Operating margin
- 15.3%
- Net margin
- 15.3%
- Return on equity
- 2.2%
- Return on assets
- 1.7%
- Return on capital (ROCE)
- 2.1%
- Liabilities / assets
- 21.8%
- Debt / equity
- 0.28×
- Book value / share
- $11.09
- Revenue growth (YoY)
- 4094.6%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2014- Altman Z″ (distress)
- 8.57safe
- Accruals / assets
- −15.6%clean
- Piotroski F-Score
- 6/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 6 good- Operating margin is positive
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Positive operating cash flow
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Halvorson Eric HDirector | May 26, 2015 | U | 1,000 | $261.25 |
| Booth Robert F.Director | May 26, 2015 | D | 10,000 | $261.25 |
| Van Den Broek RichardDirector | May 26, 2015 | U | 29,610 | $261.25 |
| Smith David DuaneDirector | May 26, 2015 | U | 3,000 | $261.25 |
| Tan HeowOfficer — Chief Quality&Tech Operations | May 26, 2015 | U | 11,721 | $261.25 |
| Tomasello ShawnOfficer — Chief Commercial Officer | May 26, 2015 | D | 50,000 | $261.25 |
| Soni Manmeet SinghOfficer — Chief Financial Officer | May 26, 2015 | D | 54,000 | $261.25 |
| Zanganeh MakyOfficer — Chief Operating Officer | May 26, 2015 | D | 15,000 | $261.25 |
| Duggan Robert WOfficer — Chairman and CEO | Mar 17, 2015 | Gift | 152,635 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Amended charter or bylaws · Other material eventMay 26, 2015
- Results of operationsMay 1, 2015
- Entered a material agreementMar 23, 2015
- Other material eventMar 17, 2015
- Entered a material agreement · Director / officer change · Amended charter or bylaws · Other material eventMar 6, 2015
- Other material eventMar 5, 2015
- Regulation FD disclosureFeb 20, 2015
- Results of operationsFeb 18, 2015
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- CT ORDERJun 15, 2015
- SC 13G/APCYC AS OF 05/31/2015Jun 10, 2015
- 15-12GJun 5, 2015
- SC 13D/AJun 1, 2015
- 4FORM 4 SUBMISSIONMay 28, 2015
- 4FORM 4 SUBMISSIONMay 28, 2015
- 4FORM 4 SUBMISSIONMay 28, 2015
- 4FORM 4 SUBMISSIONMay 28, 2015
- 4FORM 4 SUBMISSIONMay 28, 2015
- 4FORM 4 SUBMISSIONMay 28, 2015
- 4FORM 4 SUBMISSIONMay 28, 2015
- 4FORM 4 SUBMISSIONMay 28, 2015
- 4FORM 4 SUBMISSIONMay 28, 2015
- 4FORM 4 SUBMISSIONMay 28, 2015
- 4FORM 4 SUBMISSIONMay 28, 2015
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.